Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Aspirin | Bleeding | China Health | Cholesterol | Clinical Trials | Clopidogrel | Crestor | Diabetes | Drugs & Pharmacology | Endocrinology | Ischemic Stroke | Liver | Plavix | Rosuvastatin | Statin Therapy | Stroke | Study | Urology & Nephrology